FOXA1-overexpressing cells grow significantly faster than control cells even under fulvestrant treatment, suggesting that increased FOXA1 expression induces cellular tolerance to anti-ER treatment in breast cancer [12]. The gene discussed is ESR1; the disease is breast carcinoma.